Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_assertion type Assertion NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_head.
- NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_assertion description "[The aim of this study was to evaluate whether the neoadjuvant use of the dexamethasone (DEX) plus octreotide (OCT) regimen can improve the direct anticancer effects of docetaxel (DOC) in the TRAMP-C1 prostate cancer model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_provenance.
- NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_assertion evidence source_evidence_literature NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_provenance.
- NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_assertion SIO_000772 22210719 NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_provenance.
- NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_assertion wasDerivedFrom befree-2016 NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_provenance.
- NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_assertion wasGeneratedBy ECO_0000203 NP950290.RAgTtSHxsHRFlatYQ5axnGNcjyd-ToOFktVS1z9wl6iQo130_provenance.